28th April 2026
30th March 2026
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519
18th March 2026
Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat Cancer
9th February 2026
Lilly to acquire Orna Therapeutics to advance cell therapies
9th January 2026
Aktis Oncology Announces Pricing of its Upsized Initial Public Offering
22nd September 2025
The Endpoints 11: Umoja Biopharma looks to finally break through the barriers that restrict CAR-T
16th September 2025
Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)
18th August 2025
Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
25th June 2025
āshibio Doses First Patient in Phase 1b Trial of Andecaliximab in Patients with Spinal Cord Injury (SCI) at Risk of Heterotopic Ossification (HO)
4th June 2025